Amgen sets sights on Coherus over biologic drug

12-05-2017

Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.


Amgen, patent, patent infringement, Coherus Biosciences, Neulasta, Biologics Price Competition and Innovation Act, biologics, biosimilars

LSIPR